Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Contipro A S currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, LARA, CAROLINE MONSERRAT, who is the busiest examiner for the company with 1 pending case. The prosecution is occurring within 1 distinct art unit. This represents a concentrated effort on a single pharmaceutical patent application, requiring a strategy that is finely tuned to the requirements of this specific examiner.
With 1 pending office action, the company's immediate patent strategy is entirely focused on the interaction with LARA, CAROLINE MONSERRAT. The examiner's specific tendencies and the procedural norms of the 1 distinct art unit are the most important factors for the practitioner to consider. This centralized approach allows for a deep dive into the technical details of the application without the need to manage multiple examiner relationships. Practitioners should focus on providing a comprehensive response that addresses the specific concerns of the 1 distinct examiner. Since there is only 1 pending action, the company can dedicate all its resources to ensuring a successful outcome within the Biotechnology & Pharmaceuticals sector for this particular case.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LARA, CAROLINE MONSERRAT | 1 | 85.7% | +16.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18852078 | CRYOPRESERVATION MEDIUM COMPRISING HYALURONIC ACID, USE THEREOF AND METHOD OF CRYOPRESERVATION | LARA, CAROLINE MONSERRAT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18852078 | CRYOPRESERVATION MEDIUM COMPRISING HYALURONIC ACID, USE THEREOF AND METHOD OF CRYOPRESERVATION | LARA, CAROLINE MONSERRAT | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18852078 | CRYOPRESERVATION MEDIUM COMPRISING HYALURONIC ACID, USE THEREOF AND METHOD OF CRYOPRESERVATION | LARA, CAROLINE MONSERRAT | 1633 | §103 | Non-Final OA | — | Pending | Sep 27, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialContipro A S has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Caroline Monserrat Lara has the most, with 1 of Contipro A S's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
